Periowave agreement

Aug. 8, 2011
Periowave Dental Technologies has acquired an exclusive license for the disinfection and sterilization of tissues, wounds, and lesions in the oral cavity from UCL Business PLC.

TORONTO, Ontario, Canada--Periowave Dental Technologies is developing and commercializing antimicrobial photodynamic therapies for the treatment of a spectrum of bacterial, fungal, and viral infections in the oral cavity without encouraging the formation and spread of antibiotic resistance.

The photodisinfection technologies were developed by professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London.

The company’s Periowave Photodisinfection System is a simple, pain-free, nonsurgical and nonantibiotic approach for the treatment of gum disease (periodontitis, endodontics, peri-implant disease) and other oral infections.

Periowave Is Coming Ashore

Photodisinfection is a powerful nonthermal antimicrobial technology that has been proven in clinical trials to generate patient outcomes such as gains in clinical attachment and reductions in pocket depth and bleeding without requiring patient compliance.

The new license agreement will allow the company to expand the indications for its photodisinfection technology.

For more information, go to

To comment on this subject, go to